When I sat down to write this column, I hit a bit of an initial roadblock. I’ve been writing columns here for over a year…

The European Medicines Agency (EMA) will review an application for linerixibat, an experimental oral therapy for intense itching associated with primary biliary cholangitis (PBC).

As I sat down to write this week’s column, my imagination flipped on its silly switch. I couldn’t help but picture a sick cartoon liver…